CytomX Therapeutics has been granted a patent for a method involving partially reducing activatable antibodies and conjugating therapeutic or diagnostic agents with selectivity. The method includes reducing disulfide bonds in the antibody and conjugating the agent, ensuring precise placement. GlobalData’s report on CytomX Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CytomX Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. CytomX Therapeutics's grant share as of May 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Method of partially reducing and conjugating activatable antibodies
A recently granted patent (Publication Number: US11992528B2) discloses a method for partially reducing an activatable antibody and conjugating an agent to achieve selectivity in agent placement. The method involves reducing interchain disulfide bonds in the activatable antibody without affecting intrachain disulfide bonds within a masking moiety (MM) present in the antibody. This partial reduction is carried out using a specific reducing agent, tris(2-carboxyethyl)phosphine (TCEP), in a controlled ratio and time frame. Subsequently, an agent is conjugated to the partially reduced activatable antibody, which includes an antibody or antigen-binding fragment that specifically targets a particular antigen. The activatable antibody also contains a cleavable moiety (CM) that acts as a substrate for a protease, enabling targeted delivery of the agent.
Furthermore, the patent claims detail various aspects of the method, including the structural arrangement of the activatable antibody in its uncleaved state, the types of agents that can be conjugated (such as toxins or detectable moieties), the use of cleavable linkers for conjugation, and the properties of the masking moiety (MM) and cleavable moiety (CM). Additionally, the patent covers the specific enzymes that can cleave the CM, such as urokinase plasminogen activator (uPA), legumain, matriptase, and matrix metalloproteases (MMPs), with specific mention of MMP-9 and MMP-14. This method offers a novel approach to enhancing the selectivity and efficacy of antibody-based therapies by precisely delivering therapeutic or diagnostic agents to targeted sites within the body, potentially improving treatment outcomes for various diseases.
To know more about GlobalData’s detailed insights on CytomX Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
